Wockhardt Equips Drug Discovery Researchers with ACD/Labs Software
Bangalore, India, and Aurangabad, Maharastra, (February 6, 2007)— Advanced Chemistry Development, Inc., (ACD/Labs) is pleased to announce that the Wockhardt Research Centre, Aurangabad, has equipped its new drug research facility with ACD/Labs NMR Predictors, NMR Managers, and ACD/Structure Design Suite.
The ACD/Labs NMR data management and prediction packages will assist Wockhardt scientists in their efforts to efficiently elucidate new compounds, and store the resulting spectral data in a database with assigned chemical structures. This software will help improve the efficiency of lead optimization efforts by suggesting favorable structural modifications to the lead compounds; obtaining optimal physicochemical properties (lipophilicity, solubility, etc.).
“We are investing in talent and technology to accelerate our new drug discovery programme,” said Dr. B. K. Trivedi, Chief Scientific Officer, Wockhardt Research Centre. “Our new chemical entity, WCK 771, is the first anti-infective molecule in India to enter Phase II clinical trials. The ACD/Labs software is expected to enhance the efficiency of our medicinal chemistry operations.”
“ACD/Structure Design Suite is the flagship product of our PhysChem product line, which also offers predicted values for properties such as solubility, pKa, logP, and logD,” said K. K. Bhagchandani, Director of Asia Pacific Operations for ACD/Labs. “It brings together the strength of ACD/Labs’ accurate property predictions and integrates them into a lead optimization workflow to help focus synthetic efforts in drug discovery. By adding our NMR tools, Wockhardt can significantly increase the efficiency of NMR interpretation and spectroscopic validation of structures, and create an in-house database of NMR Spectroscopy data. These tools will be very helpful to the medicinal chemistry team and we look forward to hearing about the success of their endeavors.”
For more information about ACD/Labs products, visit:
http://www.acdlabs.com/nmr/
http://www.acdlabs.com/sds/
About Advanced Chemistry Development
Advanced Chemistry Development, Inc., (ACD/Labs) is a chemistry software company offering solutions that truly integrate chemical structures with analytical chemistry information to produce ChemAnalytics™. ACD/Labs creates innovative software packages that aid chemical research scientists worldwide with spectroscopic validation of structures, elucidation of unknown substances, chromatographic separation, medicinal chemistry, preformulation of novel drug agents, systematic nomenclature generation, and chemical patenting and publication. Combined, ACD/Labs’ solutions create an analytical informatics system that provides dramatic feed-forward effects on the chemical and pharmaceutical research process. Founded in 1994, and headquartered in Toronto, Canada, ACD/Labs employs a team of over 145 dedicated individuals whose continual efforts carry ACD/Labs’ innovative technologies into pharmaceutical, biotech, chemical, and materials companies throughout the world. Information about Advanced Chemistry Development and its products can be found at www.acdlabs.com.
About the Wockhardt Research Centre
The Drug Discovery team at Wockhardt has developed a number of lead molecules in the anti-infective field that are currently in various stages of development. The most advanced of these New Chemical Entities (NCEs) is WCK 771 that has commenced Phase II human clinical trials. WCK 771 is a broad-spectrum anti-MRSA antibiotic. Many US patents have been granted to Wockhardt for this NCE and the molecule has been extensively reviewed in scientific journals and international conferences. Wockhardt is a technology-driven pharmaceutical and biotechnology company with an active multi-disciplinary programme employing 400 scientists. The US and European Union contributes to half of Wockhardt’s turnover. Wockhardt has a market capitalization of $1.3 billion. For more information, visit www.wockhardt.com
